ArticlePloS one2025
Survival analysis and clinical abnormalities in cats with progressive or regressive feline leukemia virus (FeLV) infection in Brazil.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical and virological effects of the integrase inhibitor raltegravir in cats with naturally progressive feline leukaemia virus infection.Journal of feline medicine and surgery · 2026Article
- Article
- Editorial: Advancements in feline oncology: diagnosis, treatment, and management of domestic cat cancers.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to characterize the clinical presentations and effects of progressive and regressive outcomes of feline leukemia virus (FeLV) infection on the life expectancy of cats. In total, 176 cats were selected: 116 with progressive infection (FeLV+P), 30 with regressive infection (FeLV+ R), and 30 FeLV-negative cats (Control). The cats underwent testing using ELISA to detect the FeLV p27 antigen and nested polymerase chain reaction to identify U3-LTR region and gag proviral DNA. The cats were clinically monitored until their death or for a period ranging 12-54 months. Survival analysis was performed using Kaplan-Meier analysis and Cox regression. The median survival time following FeLV diagnosis was 30 days for the FeLV+P group. The median survival time was not reached for the other groups. The cats' health status (sick) at the time of inclusion in the study and the progression status of the FeLV infection led to a 4-5-fold increase in the Hazard Ratio (HR) for death in the general population. The primary causes of death among cats in the FeLV+P group were lymphoma, leukemia, anemia, and other diseases. In the FeLV+R group, the causes of death included leukemia, anemia, and other diseases. Progressive FeLV infection reduced life expectancy, whereas regressive FeLV infection had no direct impact on the survival curve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.